Seeking Alpha

Allergan (AGN) agrees to acquire MAP Pharmaceuticals (MAPP) for $958M ($25/share) in cash, a 60%...

Allergan (AGN) agrees to acquire MAP Pharmaceuticals (MAPP) for $958M ($25/share) in cash, a 60% premium over MAP's Tuesday close. MAP's experimental migraine drug Levadex is set to receive a regulatory decision by April 15; Botox maker Allergan (which already had rights to help market Levadex) is showing confidence in an OK by taking total control.
Comments (1)
  • chanyerv@gmail.com
    , contributor
    Comments (2) | Send Message
     
    good stock I have made 36% in 2 years.
    23 Jan 2013, 07:09 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|